Figure 7.

 Site‐specific relapse‐free survival in colorectal cancer patients with stage II and III tumors (n = 82). The patients in stage II and III developed disease recurrence: liver metastasis (n = 8); lung metastasis (n = 5); bone metastasis (n = 1); local recurrence (n = 3); and lymph node metastasis (n = 3). Among them, one patient had both liver metastasis and lung metastasis, and another had both liver metastasis and local recurrence. The cases were categorized as: (A) translocation from cytoplasm to membrane and with enhanced intensity; (B1) translocation but without enhanced intensity; (B2) no translocation but with enhanced intensity; or (C) no translocation and without enhanced intensity. Type A C4.4A expression was linked to shorter liver metastasis‐free survival rate, lung metastasis‐free survival rate, or hematogenous metastasis‐free survival (P = 0.0279, P = 0.0061, and P = 0.0006, respectively). No difference was observed in other site‐specific disease‐free survival curves (data not shown).